Leleu Xavier

Hématologie

Hôpital La Miletrie
Poitiers, France

779 Activités

2 Followers

Scientifique

Digital

Production scientifique

Activités par an

Expertise

Sujets de recherche

Myélome multiple Tumeurs à plasmocytes Macroglobulinémie de Waldenström Récidive tumorale locale Amyloïdose Leucémies Amylose à chaine légère d'immunoglobuline Lymphomes Neuropathies périphériques

Collaborateurs

Moreau Philippe

Hôpital Hôtel-Dieu Nantes, Nantes, France

Facon Thierry

Hôpital Huriez, Lille, France

Hulin Cyrille

Hôpital Haut-lévêque, Pessac, France

Avet-Loiseau Herve

Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

Industries

Janssen

72 collaboration(s)

Dernière en 2023

Sanofi

60 collaboration(s)

Dernière en 2023

Takeda Pharmaceutical

38 collaboration(s)

Dernière en 2023

GSK

37 collaboration(s)

Dernière en 2023

Dernières activités

KarMMa-9: A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Essai Clinique (BMS) 18 mars 2024

RHUMM: Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma RHU(M)M Random or H24 Urine in (Multiple) Myeloma

Essai Clinique (Intergroupe Francophone du Myélome) 15 mars 2024

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma: An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma

Essai Clinique (Janssen) 11 mars 2024

Clinical Advances in Immunotherapy For Multiple Myeloma

Medscape 02 mars 2024

CANDOR: A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Essai Clinique (Amgen) 01 mars 2024

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy